NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
Trending
StrikesCrisisMilitaryTariffTrumpPrivateFebruaryGovernmentAnnounceTimelineWinCourtFacesOscarMajorNewsDigestElectionProtestsSignificantAdditionalIranianSupremeTrump's
StrikesCrisisMilitaryTariffTrumpPrivateFebruaryGovernmentAnnounceTimelineWinCourtFacesOscarMajorNewsDigestElectionProtestsSignificantAdditionalIranianSupremeTrump's
All Articles
STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study
STAT News
Clustered Story
Published about 4 hours ago

STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study

STAT News · Feb 23, 2026 · Collected from RSS

Summary

And other biotech news brought to you by The Readout

Full Article

And other biotech news brought to you by The Readout Adobe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. We’ve got some big acquisition news today, and also some politics — specifically a look at how pharma lobbyists, who have longed considered the FDA something of a fortress, now see real opportunity to exert influence. Also, read up on a Phase 3 miss from Gossamer Bio, and why it’s going to seek an approval anyway. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter.

Share this story
Read Original at STAT News

Related Articles

Bloombergabout 3 hours ago
Novo Nordisk CSO on New Obesity Shot Results and Drug Pipeline

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks on "Bloomberg Open Interest." (Source: Bloomberg)

Bloombergabout 7 hours ago
Novo Nordisk Trial Flop Ripples Through Denmark’s Stock Market

Disappointing data from Novo Nordisk A/S is sending shockwaves across equities in Denmark, dragging the wider market down and underscoring how tightly the country’s fortunes are tied to the obesity-drug maker.

STAT Newsabout 8 hours ago
STAT+: Novo Nordisk’s next-gen obesity drug stumbles in comparison study

Novo Nordisk's next-generation obesity drug CagriSema underperformed versus Eli Lilly's Zepbound in a head-to-head study.

Financial Timesabout 8 hours ago
Novo Nordisk shares drop after poor trial results for new obesity drug

Once-a-week injection achieved weight loss of 23%, which is lower than some existing treatments

STAT Newsabout 2 hours ago
STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications

The FDA expects a flood of applications for a new "plausible mechanism pathway" for approval of bespoke gene-editing treatments.

STAT Newsabout 2 hours ago
STAT+: Medicare’s AI ‘modernization’ project, and the Ohio hospital antitrust battle

Would you trust AI to help you pick your Medicare plan?